Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia

Blood

Volumn 113, Issue 19, 2009, Pages 4512-4520

  French, Deborah ^a   Yang, Wenjian ^a   Cheng, Cheng ^a   Raimondi, Susana C ^a,b   Mullighan, Charles G ^a   Downing, James R ^a   Evans, William E ^a,b   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE POLYGLUTAMATE; SMAD2 PROTEIN; SMAD4 PROTEIN; ACTIN BINDING PROTEIN; CATION TRANSPORT PROTEIN; DRUG DERIVATIVE; FHOD3 PROTEIN, HUMAN; MALATE DEHYDROGENASE; MALIC ENZYME 2; HUMAN; METHOTREXATE; MYO INOSITOL 1 (OR 4) MONOPHOSPHATASE; MYO-INOSITOL-1 (OR 4)-MONOPHOSPHATASE; PHOSPHATASE; POLYGLUTAMIC ACID; RASSF4 PROTEIN, HUMAN; SLC39A6 PROTEIN, HUMAN; SMAD2 PROTEIN, HUMAN; SMAD4 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 18; CONTROLLED STUDY; FEMALE; FHOD3 GENE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; IMPA2 GENE; LEUKEMIA; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; ME2 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; RASSF4 GENE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SLC39A6 GENE; SOMATIC CELL; CELL CULTURE; CELL LINE; COMPARATIVE STUDY; DNA MICROARRAY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN GENOME; INFANT; METABOLISM; PATHOLOGY; PHENOTYPE;

CATION TRANSPORT PROTEINS; CELL LINE, TRANSFORMED; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME, HUMAN; HUMANS; INFANT; MALATE DEHYDROGENASE; MALE; METHOTREXATE; MICROFILAMENT PROTEINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PHOSPHORIC MONOESTER HYDROLASES; POLYGLUTAMIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SMAD2 PROTEIN; SMAD4 PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 66549095339     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-172106     Document Type: Article

References (61)

1. Schlieben S, Borkhardt A, Reinisch I, et al. Incidence and clinical outcome of children with BCR/ ABL-positive acute lymphoblastic leukemia (ALL): a prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia. 1996;10:957-963. (Pubitemid 26235927)
2. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3:639-649. (Pubitemid 37328819)
3. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
4. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
5. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
6. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia. 2000;14:2234-2239.
7. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218. (Pubitemid 32183741)
8. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896-904. (Pubitemid 46220632)
9. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-4489.
10. Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am. 2008;55:1-20. (Pubitemid 351173191)
11. Schultz KR, Pullen DJ, Sather HN, et al. Riskand response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109: 926-935.
12. Evans WE, Crom WR, Stewart CF, et al. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet. 1984;1:359-362.
13. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med. 1986;314:471-477.
14. Belkov VM, Krynetski EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 1999;93:1643-1650.
15. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J Clin Invest. 1996;97:73-80. (Pubitemid 26021696)
16. Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol. 1980;17:105-110. (Pubitemid 10176280)
17. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics 10. J Clin Invest. 2005;115: 110-117. (Pubitemid 40385511)
18. Whitehead VM, Payment C, Cooley L, et al. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2001;15:1081-1088. (Pubitemid 32717278)
19. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate- polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994;94:1996-2001.
20. Barredo JC, Synold TW, Laver J, et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood. 1994;84:564-569. (Pubitemid 24215957)
21. Matherly LH, Taub JW, Wong SC, et al. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood. 1997;90: 578-589.
22. Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 1997;89:1013-1018. (Pubitemid 27121295)
23. Sorich MJ, Pottier N, Pei D, et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008; 5:e83.
24. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte- colony stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003;101:3862-3867.
25. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004; 104:2690-2696. (Pubitemid 39434949)
26. Pui CH, Relling MV, Sandlund JT, et al. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol. 2004;83[suppl 1]:S124-S126.
27. Cheok MH, Yang W, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet. 2003;34:85-90. (Pubitemid 36548796)
28. Dervieux T, Hancock ML, Pui CH, et al. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther. 2003;73:506-516. (Pubitemid 37249121)
29. Panetta JC, Yanishevski Y, Pui CH, et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2002;50:419-428. (Pubitemid 35440531)
30. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J Clin Invest. 1996;97:73-80. (Pubitemid 26021696)
31. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate- polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994;94:1996-2001.
32. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide. Los Angeles, CA: Biomedical Simulations Resource; 1990.
33. Galpin AJ, Schuetz JD, Masson E, et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol. 1997;52:155-163. (Pubitemid 27318631)
34. Fabre G, Matherly LH, Favre R, Catalin J, Cano JP. In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells. Cancer Res. 1983;43:4648-4652.
35. Kamen BA, Winick N. Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzymol. 1986;122:339-346. (Pubitemid 16017526)
36. Dervieux T, Orentas LD, Marcelletti J, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem. 2003;49:1632-1641. (Pubitemid 37194217)
37. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951-2959. (Pubitemid 37248870)
38. French D, Yang W, Hamilton LH, et al. Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS ONE. 2008;3:e2144. (Pubitemid 352025164)
39. Huang RS, Duan S, Bleibel WK, et al. A genomewide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007;104:9758-9763. (Pubitemid 47175340)
40. Lin M, Wei LJ, Sellers WR, et al. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004;20:1233-1240. (Pubitemid 38807579)
41. Mullighan CG, Goorha S, Radtke I, et al. Genome- wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446:758-764. (Pubitemid 46582031)
42. Mullighan CG, Miller CB, Radtke I, et al. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110-114. (Pubitemid 351630327)
43. Raimondi S, Mathew P, Pui C-H. Cytogenetics as a diagnostic aid for childhood hematological disorders: conventional cytogenetic techniques, fluorescence in situ hybridization, comparative genomic hybridization. In: Hanausek M, Walaszek Z, eds. Methods in Molecular Biology. Totowa, NJ: Humana Press; 1998: 209-227.
44. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1:133-143.
45. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia 2. Blood. 2004;103:1043-1049. (Pubitemid 38129570)
46. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.
47. Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood. 2003;102:2756-2762. (Pubitemid 37248844)
48. Kawamata N, Ogawa S, Zimmermann M, et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood. 2008;111:776-784.
49. Heerema NA, Raimondi SC, Anderson JR, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007;46:684-693.
50. Raimondi SC, Pui C-H, Hancock ML, et al. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia. 1996;10:213-224.
51. Gee NS, Ragan CI, Watling KJ, et al. The purification and properties of myo-inositol monophosphatase from bovine brain. Biochem J. 1988;249:883-889.
52. Fernandes DJ, Sur P, Kute TE, Capizzi RL. Proliferation- dependent cytotoxicity of methotrexate in murine L5178Y leukemia. Cancer Res. 1988;48: 5638-5644. (Pubitemid 18248117)
53. van Triest B, Pinedo HM, van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res. 1999;5:643-654.
54. Whitehead VM, Vuchich MJ, Cooley LD, et al. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Leuk Lymphoma. 1998; 31:507-519. (Pubitemid 29050592)
55. Wonsey DR, Zeller KI, Dang CV. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci U S A. 2002;99:6649-6654.
56. Chang TS, Cho CS, Park S, et al. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem. 2004;279:41975-41984. (Pubitemid 39313648)
57. Cavalieri D, Dolara P, Mini E, et al. Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer. Oncol Res. 2007;16:535-548. (Pubitemid 351211326)
58. Cheng Q, Yang W, Raimondi SC, et al. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet. 2005;37:878-882. (Pubitemid 41077115)
59. Harris MB, Shuster JJ, Carroll A, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992;79:3316-3324.
60. Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia. 2005; 19:734-740.
61. Cheng Q, Evans WE. Cancer pharmacogenomics may require both qualitative and quantitative approaches. Cell Cycle. 2005;4:1506-1509.